3T multiparametric MRI’s accuracy in detecting prostate cancer using Prostate Imaging Reporting and Data System (PIRADS) version 2.1 with prostate biopsy as a reference

Abstract

Multiparametric magnetic resonance imaging (MRI) is valuable in detecting prostate cancer due to its high sensitivity to malignant lesions. It is commonly utilized to improve the identification of clinically significant cancers within the prostate. This study aimed to correlate the findings from 3T multiparametric MRI of the prostate using the updated Prostate Imaging Reporting and Data System version 2.1 (PIRADSv2.1) from 2019 with reference to prostate biopsy results. Additionally, PIRADSv2.1 was used to calculate the sensitivity, specificity, positive predictive value, and negative predictive value of the 3T multiparametric MRI of the prostate. A retrospective study was conducted at a tertiary center, wherein we identified patients who underwent a prostate biopsy between June 2019 and June 2021 and had a corresponding MRI of the prostate performed at the same institution, evaluated with PIRADSv2.1 criteria. A total of 50 patients were eligible for final analysis. The prevalence of prostate cancer was 69% (95% confidence interval (CI) 54–81%). Receiver operating characteristic (ROC) curves were generated for 3T multiparametric MRI of the prostate using PIRADSv2.1 to diagnose prostate cancer; the area under the ROC curve was 0.81 (95% CI 0.68–0.95, p < 0.001). The sensitivity, specificity, positive predictive value, and negative predictive value of the 3T multiparametric prostate MRI using PIRADSv2.1 were 74.0%, 87.0%, 92.9%, and 59.1%, respectively. PIRADSv2.1 exhibited good overall performance in the diagnosis of prostate cancer.